Intranasal H5N1 vaccines, adjuvanted with chitosan derivatives, protect ferrets against highly pathogenic influenza intranasal and intratracheal challenge

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Mann, Alex J ^a   Noulin, Nicolas ^a   Catchpole, Andrew ^a   Stittelaar, Koert J ^b   De Waal, Leon ^b   Veldhuis Kroeze, Edwin J B ^b   Hinchcliffe, Michael ^c,j   Smith, Alan ^c   Montomoli, Emanuele ^d,e   Piccirella, Simona ^e   Osterhaus, Albert D M E ^b,f   Knight, Alastair ^g   Oxford, John S ^a   Lapini, Giulia ^d   Cox, Rebecca ^h,i   Lambkin Williams, Rob ^a  

^a Retroscreen Virology   (United Kingdom)

^b Viroclinics Biosciences BV   (Netherlands)

^c Albert Einstein Centre   (United Kingdom)

^d UNIVERSITY OF SIENA   (Italy)

^e VisMederi Srl   (Italy)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g Somerset House   (United Kingdom)

^h UNIVERSITY OF BERGEN   (Norway)

ⁱ HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^j Paracelsis Ltd   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; CHITOSAN DERIVATIVE; INFLUENZA VACCINE; PLACEBO; VIRUS ANTIBODY; CHITOSAN; IMMUNOLOGICAL ADJUVANT; NEUTRALIZING ANTIBODY; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BRAIN; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; CROSS REACTION; DRUG DOSAGE FORM COMPARISON; HISTOPATHOLOGY; INFLUENZA A (H5N1); LUNG PARENCHYMA; MALE; MORBIDITY; MORTALITY; NONHUMAN; OLFACTORY BULB; RESPIRATORY SYSTEM; THROAT CULTURE; TURBINATE; VIROLOGY; VIRUS IMMUNITY; VIRUS REPLICATION; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; DOG; FERRET; HUMAN; IMMUNOLOGY; INFLUENZA VIRUS A H5N1; INFLUENZA, HUMAN; INTRANASAL DRUG ADMINISTRATION; MDCK CELL LINE; NOSE; OUTBRED STRAIN; TRACHEA; VACCINATION; VIRUS LOAD;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANIMALS, OUTBRED STRAINS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHITOSAN; DOGS; FERRETS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MADIN DARBY CANINE KIDNEY CELLS; MALE; NOSE; TRACHEA; VACCINATION; VACCINE POTENCY; VIRAL LOAD;

EID: 84901314963     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093761     Document Type: Article

References (41)

1. WHO/PED (2003-2012) Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO, 2003-2012. WHO Report.
2. WHO (2012) Influenza at the human-animal interface. http://wwwwhoint/ influenza/human-animal-interface/Influenza-Summary-IRA-HA-interface- 17Dec12updatedpdf.
3. Buchy P, Mardy S, Vong S, Toyoda T, Aubin JT, et al. (2007) Influenza A/H5N1 virus infection in humans in Cambodia. J Clin Virol 39: 164-168. (Pubitemid 46929004)
4. Russell CA, Fonville JM, Brown AE, Burke DF, Smith DL, et al. (2012) The potential for respiratory droplet-transmissible A/H5N1 influenza virus to evolve in a mammalian host. Science 336: 1541-1547.
5. Imai M, Watanabe T, Hatta M, Das SC, Ozawa M, et al. (2012) Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 486: 420-428.
6. WHO (2009) Continuing progress towards a unified nomenclature for the highly pathogenic H5N1 avian influenza viruses: divergence of clade 2.2 viruses. Influenza Other Respi Viruses 3: 59-62.
7. Webster RG, Govorkova EA (2006) H5N1 influenza-continuing evolution and spread. N Engl J Med 355: 2174-2177.
8. Govorkova EA, Webby RJ, Humberd J, Seiler JP, Webster RG (2006) Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J Infect Dis 194: 159-167. (Pubitemid 44087186)
9. Baras B, Stittelaar KJ, Simon JH, Thoolen RJ, Mossman SP, et al. (2008) Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS One 3: e1401.
10. Middleton D, Rockman S, Pearse M, Barr I, Lowther S, et al. (2009) Evaluation of vaccines for H5N1 influenza virus in ferrets reveals the potential for protective single-shot immunization. J Virol 83: 7770-7778.
11. Chowell G, Miller MA, Viboud C (2008) Seasonal influenza in the United States, France, and Australia: transmission and prospects for control. Epidemiol Infect 136: 852-864. (Pubitemid 351524020)
12. Kuiken T, van den Brand J, van Riel D, Pantin-Jackwood M, Swayne DE (2010) Comparative pathology of select agent influenza a virus infections. Vet Pathol 47: 893-914.
13. Maher JA, DeStefano J (2004) The ferret: an animal model to study influenza virus. Lab Anim (NY) 33: 50-53. (Pubitemid 351494810)
14. Mann A, Marriott AC, Balasingam S, Lambkin R, Oxford JS, et al. (2006) Interfering vaccine (defective interfering influenza A virus) protects ferrets from influenza, and allows them to develop solid immunity to reinfection. Vaccine 24: 4290-4296.
15. Bodewes R, Kreijtz JH, van Amerongen G, Geelhoed-Mieras MM, Verburgh RJ, et al. (2010) A single immunization with CoVaccine HT-adjuvanted H5N1 influenza virus vaccine induces protective cellular and humoral immune responses in ferrets. J Virol 84: 7943-7952.
16. van der Laan JW, Herberts C, Lambkin-Williams R, Boyers A, Mann AJ, et al. (2008) Animal models in influenza vaccine testing. Expert Rev Vaccines 7: 783-793.
17. EMEA (2007) Guidelines on Influenza vaccines prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context. EMEA Guidelines.
18. Bodewes R, Rimmelzwaan GF, Osterhaus AD (2010) Animal models for the preclinical evaluation of candidate influenza vaccines. Expert Rev Vaccines 9: 59-72.
19. Jabbal-Gill I, Watts P, Smith A (2012) Chitosan-based delivery systems for mucosal vaccines. Expert Opin Drug Deliv 9: 1051-1067.
20. Sahni JK, Chopra S, Ahmad FJ, Khar RK (2008) Potential prospects of chitosan derivative trimethyl chitosan chloride (TMC) as a polymeric absorption enhancer: synthesis, characterization and applications. J Pharm Pharmacol 60: 1111-1119.
21. Stittelaar KJ, Veldhuis Kroeze EJ, Rudenko L, Dhere R, Thirapakpoomanunt S, et al. (2011) Efficacy of live attenuated vaccines against 2009 pandemic H1N1 influenza in ferrets. Vaccine 29: 9265-9270.
22. Palmer DF, Dowle WR, Coleman MT, Schild GC (1975) Hemagglutination inhibition test. Advanced laboratory techniques for influenza diagnosis: procedural guide US Department of Health Education, Atlanta, GA Immunology ser. Nr. 6 Procedural guide: 25-62.
23. Svindland SC, Jul-Larsen A, Pathirana R, Andersen S, Madhun A, et al. (2012) The mucosal and systemic immune responses elicited by a chitosan-adjuvanted intranasal influenza H5N1 vaccine. Influenza Other Respi Viruses 6: 90-100.
24. Spearman C (1908) The method of "right and wrong cases" ("constant stimuli") without Gauss's formulae. British Journal of Psychology 1904-1920: 227-242.
25. Karber G (1931) Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Archiv fur Experimentelle Pathologie und Pharmakologie: 480-487.
26. Schild GC, Pereira MS, Chakraverty P (1975) Single radial haemolysis: a new method for the assay of antibody to influenza haemagglutinin. Bull WHO: 43-50.
27. CHMP (1997) Note for guidance on harmonisation of requirements for influenza vaccines. EMEA Guidance Document CHMP/BWP/214/96.
28. van den Brand JM, Stittelaar KJ, Leijten LM, van Amerongen G, Simon JH, et al. (2012) Modification of the ferret model for pneumonia from seasonal human influenza A virus infection. Vet Pathol 49: 562-568.
29. Heffernan MJ, Zaharoff DA, Fallon JK, Schlom J, Greiner JW (2011) In vivo efficacy of a chitosan/IL-12 adjuvant system for protein-based vaccines. Biomaterials 32: 926-932.
30. de Jong MD (2008) H5N1 transmission and disease: observations from the frontlines. Pediatr Infect Dis J 27: S54-56.
31. de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, et al. (2006) Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 12: 1203-1207. (Pubitemid 44527358)
32. de Jong MD, Bach VC, Phan TQ, Vo MH, Tran TT, et al. (2005) Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N Engl J Med 352: 686-691. (Pubitemid 40239216)
33. Bodewes R, Kreijtz JH, van Amerongen G, Fouchier RA, Osterhaus AD, et al. (2011) Pathogenesis of Influenza A/H5N1 virus infection in ferrets differs between intranasal and intratracheal routes of inoculation. Am J Pathol 179: 30-36.
34. Rockman S, Brown L (2010) Pre-pandemic and pandemic influenza vaccines. Hum Vaccin 6: 792-801.
35. Bodewes R, de Mutsert G, van der Klis FR, Ventresca M, Wilks S, et al. (2011) Prevalence of antibodies against seasonal influenza A and B viruses in children in Netherlands. Clin Vaccine Immunol 18: 469-476.
36. Buricchi F, Bardelli M, Malzone C, Capecchi B, Nicolay U, et al. (2012) Impact of preexisting memory to seasonal A/H1N1 influenza virus on the immune response following vaccination against avian A/H5N1 virus. Eur J Immunol.
37. Lipatov AS, Hoffmann E, Salomon R, Yen HL, Webster RG (2006) Cross-protectiveness and immunogenicity of influenza A/Duck/Singapore/3/97(H5) vaccines against infection with A/Vietnam/1203/04(H5N1) virus in ferrets. J Infect Dis 194: 1040-1043. (Pubitemid 44547643)
38. Forrest HL, Khalenkov AM, Govorkova EA, Kim JK, Del Giudice G, et al. (2009) Single- and multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets. Vaccine 27: 4187-4195.
39. Rao SS, Kong WP, Wei CJ, Van Hoeven N, Gorres JP, et al. (2010) Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against H5N1 influenza in mouse and ferret. PLoS One 5: e9812.
40. Suguitan AL, Jr., Cheng X, Wang W, Wang S, Jin H, et al. (2011) Influenza H5 hemagglutinin DNA primes the antibody response elicited by the live attenuated influenza A/Vietnam/1203/2004 vaccine in ferrets. PLoS One 6: e21942.
41. Gustin KM, Maines TR, Belser JA, van Hoeven N, Lu X, et al. (2011) Comparative immunogenicity and cross-clade protective efficacy of mammalian cell-grown inactivated and live attenuated H5N1 reassortant vaccines in ferrets. J Infect Dis 204: 1491-1499.